MedTrace Logo

PS-341 in Treating Women With Metastatic Breast Cancer

NCT00028639 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2011-07-29

No results posted yet for this study

Summary

RATIONALE: PS-341 may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth.

PURPOSE: Phase II trial to study the effectiveness of PS-341 in treating women who have metastatic breast cancer.

Conditions

Interventions

DRUG

bortezomib

Sponsors & Collaborators

Principal Investigators

  • William J. Gradishar, MD · Robert H. Lurie Cancer Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-08-31
Primary Completion
2003-11-30
Completion
2003-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00028639 on ClinicalTrials.gov